Onartuzumab, an anti-MET monoclonal antibody, failed to demonstrate improved clinical outcomes when combined with mFOLFOX6 in metastatic HER2-negative GC/GEJ cancers, both in the overall population and in the MET-positive subgroup [112]. Here, ERBB2 is linked to gastric cancer.